M
Miriam Schlenk
Researcher at University of Bonn
Publications - 6
Citations - 197
Miriam Schlenk is an academic researcher from University of Bonn. The author has contributed to research in topics: Adenosine receptor & Monoamine oxidase B. The author has an hindex of 6, co-authored 6 publications receiving 168 citations.
Papers
More filters
Journal ArticleDOI
Dual Targeting of Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-ones
Anne Stößel,Miriam Schlenk,Sonja Hinz,Petra Küppers,Jag Paul Heer,Michael Gütschow,Christa E. Müller +6 more
TL;DR: By optimizing benzothiazinones for both targets, the first potent, dual-acting A2AAR/MAO-B inhibitors with a nonxanthine structure were developed and may be useful tools for validating the A1AAR-B dual target approach in PD.
Journal ArticleDOI
Benzothiazinones: a novel class of adenosine receptor antagonists structurally unrelated to xanthine and adenine derivatives.
Michael Gütschow,Miriam Schlenk,Jürgen Gäb,Minka Paskaleva,Mohamad Wessam Alnouri,Silvia Scolari,Jamshed Iqbal,Christa E. Müller +7 more
TL;DR: 2-Acylamino-3,1-benzothiazin-4-ones represent novel scaffolds suitable for the development of potent and selective AR antagonists for each of the four receptor subtypes.
Journal ArticleDOI
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Pierre Koch,Rhalid Akkari,Andreas Brunschweiger,Thomas Borrmann,Miriam Schlenk,Petra Küppers,Meryem Köse,H. Radjainia,Jörg Hockemeyer,Anna Drabczyńska,Katarzyna Kieć-Kononowicz,Christa E. Müller +11 more
TL;DR: A novel class of potent MAO-B inhibitors was discovered, the most potent compound being 9-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4(1H,3H)-dione, which displayed high selectivity versus the other investigated targets.
Journal ArticleDOI
8‐Benzyltetrahydropyrazino[2,1‐f]purinediones: Water‐Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases
Andreas Brunschweiger,Andreas Brunschweiger,Pierre Koch,Pierre Koch,Miriam Schlenk,Felipe Pineda,Petra Küppers,Sonja Hinz,Meryem Köse,Stefan Ullrich,Jörg Hockemeyer,Michael Wiese,Jag Paul Heer,Christa E. Müller +13 more
TL;DR: 8‐Benzyl‐substituted tetrahydropyrazino[2,1‐f]purine‐2,4(1H,3H)‐dione was found to be the best triple‐target drug in rat and may serve as a useful tool for preclinical proof‐of‐principle studies.
Journal ArticleDOI
8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors
Andreas Brunschweiger,Pierre Koch,Miriam Schlenk,Muhammad Rafehi,H. Radjainia,Petra Küppers,Sonja Hinz,Felipe Pineda,Michael Wiese,Jörg Hockemeyer,Jag Paul Heer,Frédéric Denonne,Christa E. Müller +12 more
TL;DR: A new series of tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione is designed to extensively explore their structure-activity-relationships allowing future in vivo explorations of the intended multi-target approach.